ENDURING -- Remote Patient Care: A New Era in Cardiovascular Disease Management

In support of improving patient care, Duke University Health System Clinical Education and Professional Development is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the health care team. The designation was based upon the quality of the educational activity and its compliance with the standards and policies of the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC).

 

image

 

 

 

Program Description: This program is designed to meet the continuing education (CE) needs of physicians, physician assistants, nurse practitioners, nurses, and other allied health professionals involved in remote patient monitoring in patients with cardiovascular disease, hypertension and diabetes mellitus.

Target Audience

Physicians

Learning Objectives

Explaining the role of RPM in improved patient engagement and medication adherence

Identifying proactive interventions based on real-time data to reduce emergency room visits and hospital admissions and reduce total cost of care, improve access and communication between patients and providers allowing for more timely and personalized care

Recognizing current AHA/ACC Guidelines for HFrEF, HFpEF, HFiEF and how RPM can improve achievement of more rapid uptitration of the pillars of GDMT known to be associated with improved outcomes and reduced costs

Identifying current AHA/ACC Guidelines for Management of Hypertension and enormous amount of RPM data showing improved BP control

Identifying current ADA Guidelines for DM and role of RPM and CGM in improving glycemic control and reduced CV outcomes

Understanding and explaining the alphabet soup of acronyms that CMS is using for CCM including RPM, CCM, RTM, APCM, etc.

Expressing how to best organize practice operations to incorporate a chronic disease management program for benefit of patients and providers

Describing the overview and future plans for CMS around CCM and CMS coding/reimbursement

Course summary
Available credit: 
  • 2.50 AMA PRA Category 1 Credit(s)™
  • 2.50 Attendance
Registration Opens: 
03/03/2025
Registration Expires: 
03/03/2027
Rating: 
0

Marat Fudim, MD (Financial relationships disclosed below)

Dr Fudim was supported by the NIH, Alleviant, Gradient, Reprieve, Sardocor, NIH and Doris Duke. He is a consultant and/or has ownership interest in Abbott, Acorai, Ajax, Alio Health, Alleviant, Artha, Astellas, Audicor, AxonTherapies, Bodyguide, Bodyport, Boston Scientific, Broadview, Cadence, Cardiosense, Cardioflow, Clinical Accelerator, CVRx, Daxor, Edwards LifeSciences, Echosens, EKO, Endotronix, Feldschuh Foundation, Fire1, FutureCardia, Gradient, Hatteras, HemodynamiQ, Impulse Dynamics, ISHI, Lumina Health, Medtronic, NovoNordisk, NucleusRx, Omega, Orchestra, Parasym, Pharmacosmos, Presidio, Procyreon, Proton Intelligence, Puzzle, ReCor, Scirent, SCPharma, Shifamed, Splendo, Summacor, SyMap, Terumo, Vascular Dynamics, Vironix, Viscardia, Zoll.

Theodore Feldman, MD (Financial relationships disclosed below)

Rightway Healthcare Cofounder and Chief Medical Officer; Cadence Health Chief Medical Officer

Eve Cunningham, MD (No financial relationships to disclose)

Randall Curnow, MD (Financial relationships disclosed below)

Cadence Employee

David Feldman, MD (Financial relationships disclosed below)

Cadence Consultant

Jason Guichard, MD (No financial relationships to disclose)

Lynn Simon, MD (Financial relationships disclosed below)

Cadence Board Observer; Forefront Dermatology Board Member

Benjamin Scirica, MD (Financial relationships disclosed below)

Dr. Scirica reports institutional research support to Brigham and Women’s Hospital from Amgen, Better Therapeutics, Boehringer Ingelheim, Foresite Labs Milestone Pharmaceutical, Merck, NovoNordisk, Pfizer, and Verve Therapeutics. Consulting fees from Abbvie (DSMB), Amgen, AstraZeneca (DSMB), Bayer, Boehringer Ingelheim (DSMB), Elsevier Practice Update Cardiology, Hanmi (DSMB), Lexeo (DSMB), NovoNordisk, Verve Therapeutics, and equity in Health [at] Scale and Arboretum Lifescience.

 

AMA PRA Category 1 Credit(s)

Available Credit

  • 2.50 AMA PRA Category 1 Credit(s)™
  • 2.50 Attendance
Please login or register to take this course.